China Biologic Announces Extraordinary General Meeting of Shareholders
News provided by
Share this article
Share this article
BEIJING, Jan. 25, 2021 /PRNewswire/ China Biologic Products Holdings, Inc. (NASDAQ: CBPO, China Biologic or the Company ), a leading fully integrated plasma-based biopharmaceutical company in China, today announced that it has called an extraordinary general meeting of shareholders (the EGM ) to be held on March 1, 2021 at 10:00 a.m. (Beijing time), at the principal office of the Company located at 18th Floor, Jialong International Building, 19 Chaoyang Park Road, Chaoyang District, Beijing, China, to consider and vote on, among other matters, the proposal to authorize and approve the previously announced agreement and plan of merger, dated as of November 19, 2020 (the Merger Agreement ), among the Company, CBPO Holdings Limited ( Parent ) and CBPO Group Limited ( Merger Sub ), the plan of merger required to be filed with the Registrar of Co
Databridgemarketresearch.com Present “
Global Plasma Therapy Market– Industry Trends and Forecast to 2027” new report to its research database. This
Global Plasma Therapy Market report is structured with the thorough market analysis carried out by a team of industry experts, dynamic analysts, skilful forecasters and well-informed researchers. And not to mention, the report is amazingly characterized by using several charts, graphs and tables depending on the extent of data and information involved. Businesses can achieve complete knowhow of general market conditions and tendencies with the information and data covered in this report. What is more, influencing factors such as market drivers, market restraints and competitive analysis is studied with the SWOT analysis which is the most established tool when it comes to generate market research report.
Share:
London, Jan. 14, 2021 (GLOBE NEWSWIRE) In its latest publication, titled Plasma Fractionation Market by Product [Immunoglobulins (Intravenous, Subcutaneous), Coagulation Factors, Albumin], Application (Immunology, Hematology, Neurology), and End User (Hospital, Clinical Research Lab, Academic Institutes) - Forecast to 2027 , Meticulous Research® states that the plasma fractionation market is expected to grow at a CAGR of 7% from 2020 to 2027 to reach $41.4 billion by 2027.
Plasma fractionation is a method of separating various components of blood plasma into its different components. Plasma-derived products are used in the prevention and treatment of life-threatening diseases caused by trauma, immunologic disorders, and infections.
The rising use of immunoglobulins in therapeutic areas, increasing number of chronic diseases, growing prevalence of blood and respiratory disorders, and rising number of plasma collection centers are some of the major factors driving the
Search jobs 18-Dec-2020 Global Guillain-Barre Syndrome Market 2020 Research Analysis, Innovative Services And Advanced Applications, Future Growth Till 2027||Nihon Pharmaceutical Co., Ltd., CSL Behring LLC, Shire plc, Akari Therapeutics, PLC
“Global Guillain-Barre Syndrome Market–Industry Trends and Forecast to 2028” New Research Report Added to Databridgemarketresearch.com database. The report width Of pages : 350 Figures: 60 And Tables: 220 in it.The global Guillain-Barre Syndrome market is highly fragmented and the major players have used various strategies such as new product launches, expansions, agreements, joint ventures, partnerships, acquisitions and others to increase their footprints in this market. The report includes market shares of Guillain-Barre Syndrome market for global, Europe, North America, Asia Pacific and South America.